Respiratory Syncytial Virus–Associated Hospitalization in Adults With Comorbidities in 2 European Countries: A Modeling Study

Richard Osei-Yeboah; Caroline Klint Johannesen; Amanda Marie Egeskov-Cavling; Junru Chen; Toni Lehtonen; Arantxa Urchueguía Fornes; John Paget; Thea K. Fischer; Xin Wang; Harish Nair; Harry Campbell; Hanna Nohynek; Anne Teirlinck; Michiel van Boven; Terho Heikkinen; Louis Bont; Peter Openshaw; Phillipe Beutels; Andrew Pollard; Veena Kumar; Alexandro Orrico Sánchez; David Gideonse; Tin Tin Htar; Charlotte Vernhes; Gael Dos Santos; Rachel Cohen; Jeroen Aerssens; Rolf Kramer; Ombeline Jollivet; Nuria Manchin; PROMISE Investigators

doi:10.1093/infdis/jiad510

Respiratory Syncytial Virus–Associated Hospitalization in Adults With Comorbidities in 2 European Countries: A Modeling Study

Richard Osei-Yeboah, Caroline Klint Johannesen, Amanda Marie Egeskov-Cavling, Junru Chen, Toni Lehtonen, Arantxa Urchueguía Fornes, John Paget, Thea K. Fischer, Xin Wang^*, Harish Nair, Harry Campbell, Hanna Nohynek, Anne Teirlinck, Michiel van Boven, Terho Heikkinen, Louis Bont, Peter Openshaw, Phillipe Beutels, Andrew Pollard, Veena KumarAlexandro Orrico Sánchez, David Gideonse, Tin Tin Htar, Charlotte Vernhes, Gael Dos Santos, Rachel Cohen, Jeroen Aerssens, Rolf Kramer, Ombeline Jollivet, Nuria Manchin, PROMISE Investigators

^*Corresponding author af dette arbejde

Afdeling for Global Sundhed

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

21 Citationer (Scopus)

Abstract

Background
Individuals with comorbidities are at increased risk of severe respiratory syncytial virus (RSV) infection. We estimated RSV-associated respiratory hospitalization among adults aged ≥45 years with comorbidities in Denmark and Scotland.

Methods
By analyzing national hospital and virologic data, we estimated annual RSV-associated hospitalizations by 7 selected comorbidities and ages between 2010 and 2018. We estimated rate ratios of RSV-associated hospitalization for adults with comorbidity than the overall population.

Results
In Denmark, annual RSV–associated hospitalization rates per 1000 adults ranged from 3.1 for asthma to 19.4 for chronic kidney disease (CKD). In Scotland, rates ranged from 2.4 for chronic liver disease to 9.0 for chronic obstructive pulmonary disease (COPD). In both countries, we found a 2- to 4-fold increased risk of RSV hospitalization for adults with COPD, ischemic heart disease, stroke, and diabetes; a 1.5- to 3-fold increased risk for asthma; and a 3- to 7-fold increased risk for CKD. RSV hospitalization rates among adults aged 45 to 64 years with COPD, asthma, ischemic heart disease, or CKD were higher than the overall population.

Conclusions
This study provides important evidence for identifying risk groups and assisting health authorities in RSV vaccination policy making.

Originalsprog	Engelsk
Tidsskrift	Journal of Infectious Diseases
Vol/bind	229
Sider (fra-til)	S70-S77
Antal sider	8
ISSN	0022-1899
DOI	https://doi.org/10.1093/infdis/jiad510
Status	Udgivet - 2024

Bibliografisk note

Funding Information:
This work was supported by funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant 101034339 to PROMISE); Nanjing Medical University Talents Start-up Grants (grant NMUR20210009 to X. W.); and the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (to the Innovative Medicines Initiative 2 Joint Undertaking). We acknowledge the support of the eDRIS team (electronic Data Research and Innovation Services) at Public Health Scotland for its involvement in obtaining approvals, provisioning and linking of datasets, and the use of the secure analytic platform with the National Safe Haven. We acknowledge the significant contributions of the late Dr John Paget to this study.

Funding Information:
Financial support. This work was supported by funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant 101034339 to PROMISE); Nanjing Medical University Talents Start-up Grants (grant NMUR20210009 to X. W.); and the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (to the Innovative Medicines Initiative 2 Joint Undertaking).

Funding Information:
Potential conflicts of interest. H. C. reports grants, personal fees, and nonfinancial support from the World Health Organization; grants and personal fees from Sanofi Pasteur; and grants from the Bill and Melinda Gates Foundation, outside this submitted work. H. C. is a shareholder in the Journal of Global Health Ltd. H. N. reports grants from Pfizer and Icosavax and consulting fees from the World Health Organization, Pfizer, Bill and Melinda Gates Foundation, Abbvie, and Sanofi, outside the submitted work. H. N. reports participation on a data safety monitoring board or advisory board for GSK, Sanofi, Merck, the World Health Organization, Janssen, Novavax, Resvinet, Icosavax, and Pfizer. X. W. reports grants from GlaxoSmithKline and consultancy fees from Pfizer, outside the submitted work. All other authors report no potential conflicts.

Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved.

Adgang til dokumentet

10.1093/infdis/jiad510

Citationsformater

Osei-Yeboah, R., Johannesen, C. K., Egeskov-Cavling, A. M., Chen, J., Lehtonen, T., Fornes, A. U., Paget, J., Fischer, T. K., Wang, X., Nair, H., Campbell, H., Nohynek, H., Teirlinck, A., van Boven, M., Heikkinen, T., Bont, L., Openshaw, P., Beutels, P., Pollard, A., ... PROMISE Investigators (2024). Respiratory Syncytial Virus–Associated Hospitalization in Adults With Comorbidities in 2 European Countries: A Modeling Study. Journal of Infectious Diseases, 229, S70-S77. https://doi.org/10.1093/infdis/jiad510

Osei-Yeboah, R, Johannesen, CK, Egeskov-Cavling, AM, Chen, J, Lehtonen, T, Fornes, AU, Paget, J, Fischer, TK, Wang, X, Nair, H, Campbell, H, Nohynek, H, Teirlinck, A, van Boven, M, Heikkinen, T, Bont, L, Openshaw, P, Beutels, P, Pollard, A, Kumar, V, Sánchez, AO, Gideonse, D, Htar, TT, Vernhes, C, Santos, GD, Cohen, R, Aerssens, J, Kramer, R, Jollivet, O, Manchin, N & PROMISE Investigators 2024, 'Respiratory Syncytial Virus–Associated Hospitalization in Adults With Comorbidities in 2 European Countries: A Modeling Study', Journal of Infectious Diseases, bind 229, s. S70-S77. https://doi.org/10.1093/infdis/jiad510

@article{3a3dbc7fcfe14f4f801aa3e37d01e1d8,

title = "Respiratory Syncytial Virus–Associated Hospitalization in Adults With Comorbidities in 2 European Countries: A Modeling Study",

abstract = "Background. Individuals with comorbidities are at increased risk of severe respiratory syncytial virus (RSV) infection. We estimated RSV-associated respiratory hospitalization among adults aged ≥45 years with comorbidities in Denmark and Scotland. Methods. By analyzing national hospital and virologic data, we estimated annual RSV-associated hospitalizations by 7 selected comorbidities and ages between 2010 and 2018. We estimated rate ratios of RSV-associated hospitalization for adults with comorbidity than the overall population. Results. In Denmark, annual RSV–associated hospitalization rates per 1000 adults ranged from 3.1 for asthma to 19.4 for chronic kidney disease (CKD). In Scotland, rates ranged from 2.4 for chronic liver disease to 9.0 for chronic obstructive pulmonary disease (COPD). In both countries, we found a 2- to 4-fold increased risk of RSV hospitalization for adults with COPD, ischemic heart disease, stroke, and diabetes; a 1.5- to 3-fold increased risk for asthma; and a 3- to 7-fold increased risk for CKD. RSV hospitalization rates among adults aged 45 to 64 years with COPD, asthma, ischemic heart disease, or CKD were higher than the overall population. Conclusions. This study provides important evidence for identifying risk groups and assisting health authorities in RSV vaccination policy making.",

keywords = "adults, comorbidity, hospitalization, respiratory syncytial virus",

author = "Richard Osei-Yeboah and Johannesen, {Caroline Klint} and Egeskov-Cavling, {Amanda Marie} and Junru Chen and Toni Lehtonen and Fornes, {Arantxa Urchuegu{\'i}a} and John Paget and Fischer, {Thea K.} and Xin Wang and Harish Nair and Harry Campbell and Hanna Nohynek and Anne Teirlinck and {van Boven}, Michiel and Terho Heikkinen and Louis Bont and Peter Openshaw and Phillipe Beutels and Andrew Pollard and Veena Kumar and S{\'a}nchez, {Alexandro Orrico} and David Gideonse and Htar, {Tin Tin} and Charlotte Vernhes and Santos, {Gael Dos} and Rachel Cohen and Jeroen Aerssens and Rolf Kramer and Ombeline Jollivet and Nuria Manchin and {PROMISE Investigators}",

year = "2024",

doi = "10.1093/infdis/jiad510",

language = "English",

volume = "229",

pages = "S70--S77",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Respiratory Syncytial Virus–Associated Hospitalization in Adults With Comorbidities in 2 European Countries

T2 - A Modeling Study

AU - Osei-Yeboah, Richard

AU - Johannesen, Caroline Klint

AU - Egeskov-Cavling, Amanda Marie

AU - Chen, Junru

AU - Lehtonen, Toni

AU - Fornes, Arantxa Urchueguía

AU - Paget, John

AU - Fischer, Thea K.

AU - Wang, Xin

AU - Nair, Harish

AU - Campbell, Harry

AU - Nohynek, Hanna

AU - Teirlinck, Anne

AU - van Boven, Michiel

AU - Heikkinen, Terho

AU - Bont, Louis

AU - Openshaw, Peter

AU - Beutels, Phillipe

AU - Pollard, Andrew

AU - Kumar, Veena

AU - Sánchez, Alexandro Orrico

AU - Gideonse, David

AU - Htar, Tin Tin

AU - Vernhes, Charlotte

AU - Santos, Gael Dos

AU - Cohen, Rachel

AU - Aerssens, Jeroen

AU - Kramer, Rolf

AU - Jollivet, Ombeline

AU - Manchin, Nuria

AU - PROMISE Investigators

PY - 2024

Y1 - 2024

N2 - Background. Individuals with comorbidities are at increased risk of severe respiratory syncytial virus (RSV) infection. We estimated RSV-associated respiratory hospitalization among adults aged ≥45 years with comorbidities in Denmark and Scotland. Methods. By analyzing national hospital and virologic data, we estimated annual RSV-associated hospitalizations by 7 selected comorbidities and ages between 2010 and 2018. We estimated rate ratios of RSV-associated hospitalization for adults with comorbidity than the overall population. Results. In Denmark, annual RSV–associated hospitalization rates per 1000 adults ranged from 3.1 for asthma to 19.4 for chronic kidney disease (CKD). In Scotland, rates ranged from 2.4 for chronic liver disease to 9.0 for chronic obstructive pulmonary disease (COPD). In both countries, we found a 2- to 4-fold increased risk of RSV hospitalization for adults with COPD, ischemic heart disease, stroke, and diabetes; a 1.5- to 3-fold increased risk for asthma; and a 3- to 7-fold increased risk for CKD. RSV hospitalization rates among adults aged 45 to 64 years with COPD, asthma, ischemic heart disease, or CKD were higher than the overall population. Conclusions. This study provides important evidence for identifying risk groups and assisting health authorities in RSV vaccination policy making.

AB - Background. Individuals with comorbidities are at increased risk of severe respiratory syncytial virus (RSV) infection. We estimated RSV-associated respiratory hospitalization among adults aged ≥45 years with comorbidities in Denmark and Scotland. Methods. By analyzing national hospital and virologic data, we estimated annual RSV-associated hospitalizations by 7 selected comorbidities and ages between 2010 and 2018. We estimated rate ratios of RSV-associated hospitalization for adults with comorbidity than the overall population. Results. In Denmark, annual RSV–associated hospitalization rates per 1000 adults ranged from 3.1 for asthma to 19.4 for chronic kidney disease (CKD). In Scotland, rates ranged from 2.4 for chronic liver disease to 9.0 for chronic obstructive pulmonary disease (COPD). In both countries, we found a 2- to 4-fold increased risk of RSV hospitalization for adults with COPD, ischemic heart disease, stroke, and diabetes; a 1.5- to 3-fold increased risk for asthma; and a 3- to 7-fold increased risk for CKD. RSV hospitalization rates among adults aged 45 to 64 years with COPD, asthma, ischemic heart disease, or CKD were higher than the overall population. Conclusions. This study provides important evidence for identifying risk groups and assisting health authorities in RSV vaccination policy making.

KW - adults

KW - comorbidity

KW - hospitalization

KW - respiratory syncytial virus

U2 - 10.1093/infdis/jiad510

DO - 10.1093/infdis/jiad510

M3 - Journal article

C2 - 37970679

AN - SCOPUS:85186619109

SN - 0022-1899

VL - 229

SP - S70-S77

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

ER -